PDF(Pubmed)
Abstract：
A combination of benzoyl peroxide (BPO) and tretinoin is recommended for treating acne; however, concurrent administration can be irritating, and coformulation is prevented by BPO-mediated oxidation of tretinoin. In rosacea, benzoyl peroxide has been shown to be efficacious; however, its use has been limited by poor tolerability. To overcome these limitations, the active ingredients can be encapsulated within silica microcapsules. The US Food and Drug Administration has approved 2 products using this technology, a combination of encapsulated benzoyl peroxide and encapsulated tretinoin product for acne vulgaris and encapsulated benzoyl peroxide to treat inflammatory lesions in rosacea. The active ingredients are released through small channels in the silica shell, gradually releasing the active ingredients to the skin. This study describes the stability and release profiles of encapsulated tretinoin and encapsulated benzoyl peroxide from the silica shell in physiologically relevant conditions and provides differentiation from traditional formulations.
摘要：
建议使用过氧化苯甲酰（BPO）和维甲酸联合治疗痤疮；但是，同时给药可能会有刺激性，BPO介导的维甲酸氧化可防止共制剂。在酒渣鼻，过氧化苯甲酰已被证明是有效的；然而，它的使用受到耐受性差的限制。为了克服这些限制,活性成分可以包封在二氧化硅微胶囊内。美国食品和药物管理局已经批准了2种使用该技术的产品，用于寻常痤疮的包封的过氧化苯甲酰和包封的维甲酸产品的组合和用于治疗酒渣鼻的炎性病变的包封的过氧化苯甲酰。活性成分通过二氧化硅壳中的小通道释放，逐渐向皮肤释放活性成分。这项研究描述了在生理相关条件下从二氧化硅壳中包封的维甲酸和包封的过氧化苯甲酰的稳定性和释放曲线，并提供了与传统制剂的区别。
